Belkin Celebrates Milestone of One Million Kids Headphones Sold

 

LOS ANGELES - 

With a wide variety of styles and colors, Belkin proudly marks the sale of one million units of kids' headphones worldwide

(BUSINESS WIRE) -- Belkin, a leading consumer electronics brand for 40 years, today announced a significant milestone: selling one million units of kids' headphones globally. Belkin’s diverse range of styles and colors, along with its commitment to quality, has solidified its position as a leader in kids' audio products.

Over the past several years, Belkin has made significant strides in creating high-quality audio products at its global headquarters in El Segundo, California. Utilizing expertise from seasoned acoustic engineers, Belkin has developed its signature SoundForm line, combining tasteful design and great sound for all preferences.

All Belkin audio products undergo meticulous testing to ensure top-notch quality, design, and functionality. For kids' headphones, safe volume limits guarantee a safe listening experience in both wired and wireless options. To add fun and personality, the SoundForm Mini on-ear headphones include stickers for kids to further personalize their headphones based on their unique style.

“I’m thrilled to see the growth of our kids' audio line. We’re incredibly proud of the products we’ve created, which provide fun and entertaining experiences for kids and parents,” said Steve Malony, CEO of Belkin International. “We take immense pride in designing products that are perfect for everyday use. We never cut corners with any of our products, and we always want to make sure that parents can trust Belkin to deliver quality products that are safe for their kids to use.”

Signature Sound Safety and Quality

Belkin Signature Sound is all about balance – deep bass, crystal clear vocals and crisp treble. Precision engineered to reproduce a rich, immersive home theatre sound with excellent frequency response, listeners can keep the volume at a safe level without missing a beat. With safety being a core value in all Belkin products, Belkin Signature Sound helps keep the sound clear, even at the lowest of volumes.

As part of its audio-testing process, Belkin uses special microphones to test all headphones, ensuring accurate sound measurements. Belkin follows industry standards and uses a specific test signal for consistency, along with a Bluetooth transmitter to ensure reliable test results. Instead of relying solely on its own lab results, the company confirms its findings with results from two additional independent labs. This process guarantees that Belkin headphone volume levels are accurate and safe for everyone.

Favorite Belkin Kids Audio Products:

SoundForm Mini Wired On-Ear Headphones for Kids: Premium quality headphones designed for kids, perfect for distance learning, travel, and streaming online content. These headphones feature an 85 dB volume cap, easy-to-use controls, and a durable "oops-proof" design.

SoundForm Mini Wireless On-Ear Headphones for Kids: Ideal for distance learning, long car rides, and entertainment, these wireless headphones come with an 85 dB volume cap to protect young ears and extended battery life for all-day listening.

SoundForm Nano 2 Wireless Earbuds for Kids: These earbuds bring true wireless to young listeners. Kids 7 years and older can enjoy all-day comfort with five sizes of antimicrobial ear tips with a sealed fit. Ready for plenty of songs, videos and lesson plays, Nano 2 offers 8 hours of playtime and another 20 hours of charge in the case.

SoundForm Inspire Wireless Over-Ear Headset for Kids: These comfortable, high-quality wireless headset is designed especially for kids. Fast USB-C charging brings up to 35 hours of playtime on a full charge. Safe Sound technology limits volume to 85dB while distance learning, traveling, or streaming online videos.

Availability:

The SoundForm Mini Wired On-Ear Headphones for Kids are available on Belkin.com, Amazon, and other certified retailers for $24.99 USD.

The SoundForm Mini Wireless On-Ear Headphones for Kids are available on Belkin.com, Amazon, and other certified retailers for $34.99 USD.

The SoundForm Nano 2 Wireless Earbuds for Kids are available on Belkin.com and other certified retailers for $34.99 USD.

The SoundForm Inspire Wireless Over-Ear Headset for Kids are available on Belkin.com, Amazon and other certified retailers for $39.99 USD.

For more information on Belkin Kids Headphones, please visit the website.

About Belkin

Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240627590739/en/

Permalink

https://www.aetoswire.com/en/news/2706202440158

Contacts

Jen Wei

VP of Global Communications and Corporate Development

Comms@belkin.com

QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy Development

NEWARK, Del. - Thursday, 27. June 2024

(BUSINESS WIRE)--QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy facility, and enhanced PBMC capabilities will complement existing bioanalysis, translational medicine and peripheral blood mononuclear cell (PMBC) laboratories and extend the current QPS full-service global CRO offerings.

QPS now offers clinical trial sample analysis services and leukopak cell therapy products from its newly expanded clinical trials unit conveniently located in Springfield, Missouri. In addition, QPS has also expanded PBMC service offerings from its Miami, Florida location into its Springfield, Missouri laboratories. The new facilities are housed with an existing clinical (safety) laboratory, a modern self-contained pharmacy, and dedicated space to build and ship clinical trial kits.

The modern central laboratory for sample analysis complements the existing on-site safety laboratory, equipped with the most up-to-date technologies for chemistry, urinalysis, serology, coagulation, and hematology testing. These capabilities, designed to monitor subject safety during ongoing clinical trials, will remain as core services for QPS in-house clinical trials.

The new leukopak products collection and processing facility is designed to meet the exponential growing demand for blood products to support cell therapy research and QPS is ideally placed to provide this service. QPS Missouri has a database of over 35,000 potential study participants, who can be contacted as potential blood donors for leukopak products.

“There is significant unmet demand in this rapidly growing area of cell therapy products, which represents a tremendous opportunity for QPS. Over 3,000 cell and gene therapy programs are currently in progress representing a 20% increase over the past five years. These programs require leukopak products to move forward, and as a result this market is forecasted to grow by a CAGR of more than 8% over the next six years,” said Benjamin Chien, Chairman, President and CEO of QPS.

The enhanced PBMC services include a new PBMC processing lab at the Springfield location, complementing the existing lab at QPS Miami in Miami, Florida. This new lab will support a current unmet need for PBMC processing in the midwestern USA. PBMC sample analysis is a time-consuming process, typically required in vaccine trials, and it is best done in a lab adjacent to the clinical trial unit. QPS is uniquely positioned to offer this service.

“These new facilities, services and products extend our full service CRO capabilities, putting QPS in a position to offer clients comprehensive clinical research services in one location. The central lab, PBMC lab, and the leukopack facility complement and enhance our current 240 bed clinical trials unit, safety laboratory, modern self-contained pharmacy, and clinical trial kit production facility,” said Brendon Bourg, Vice President, Early Phase Clinical and Head of Administration at QPS Missouri.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240626261072/en/

Permalink

https://www.aetoswire.com/en/news/2706202440129

Contacts

Gabrielle Pastore

1-302-635-4290

Gabrielle.Pastore@qps.com

Medisca Opens New Pharmaceutical Repackaging Facility to Meet Global Demands in Personalized Medicine

  PLATTSBURGH, N.Y. - Thursday, 27. June 2024 AETOSWire 

(BUSINESS WIRE) -- Medisca, a global leader in personalized pharmaceutical solutions, held a grand opening event on June 20, 2024, for their new repackaging and distribution facility in Plattsburgh, New York. The event was celebrated in the company of Medisca’s valued Plattsburgh team, business partners, and state and federal officials, including Congresswoman Elise Stefanik, Senator Dan Stec, and Assemblyman Billy Jones.

"This event marks the completion of the largest project ever undertaken by Medisca in our 35-year history," said Antonio Dos Santos, Medisca Founder and Chairman. “This new facility showcases the diligent efforts and dedication of Medisca people and demonstrates our commitment to supporting the growing demands in personalized medicine."

Continued investment in the North Country

After 32 years of established standing and investment in the North Country, the opening of the new Medisca facility in Plattsburgh exemplifies the value of the workforce in this region.

"The new Medisca facility is a testament to our local workforce talent pool, already providing 65 good-paying local jobs with plans for further expansion," said Congresswoman Elise Stefanik. "This significant investment in Plattsburgh underscores the strength of our region. I am proud to support Medisca and the many industries investing in our community and driving economic prosperity for hardworking families in Upstate and the North Country."

Doubling capacity to serve the growing demands in personalized medicine

Consolidating existing operations into a single site equipped with innovative machinery and automated workflows, the new facility will significantly enhance the company’s capacity to support the diverse healthcare groups it serves.

“In particular, the new facility will allow Medisca to expand its capacity to provide quality products to pharmacists and healthcare professionals, so they can prepare personalized and essential medications for patients like you and me – not just here in the United States, but across the globe,” said Sanjay Goorachurn, Medisca CEO.

Leveraging scalable innovation, reinforcing established quality systems, and prioritizing the health, safety, and wellness of Medisca personnel were paramount in every decision made during the design and construction of the new facility. Key considerations included introducing custom-tailored ISO-rated production rooms and leveraging customized warehouse management systems for end-to-end traceability.

“Taken together, the new facility is a state-of-the-art example that leverages innovation and rigorous quality and safety measures to protect our product, personnel, and environment,” said Dos Santos.

The new Medisca Plattsburgh facility has undergone a successful New York State inspection and third-party documentation and systems audit, with additional licensures and agency inspections actively underway to serve the United States and Global markets. For a look at the new facility, click here.

About Medisca

Founded in 1989, Medisca is a global leader in personalized medicine and pharmaceutical supply chain solutions. Its vast portfolio of over 2,000 products is complemented by a library of 10,000+ proprietary and customized medication formulas, expertise, and services in pharmaceutical compounding, continuing healthcare education, analytical testing, and more. Providing finely-tuned solutions to diverse wellness sectors across the globe, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.medisca.com and follow us on LinkedIn, Facebook, and YouTube.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240627482773/en/

Permalink

https://www.aetoswire.com/en/news/2706202440156

Contacts

Medisca Communications

communications@medisca.com

1-800-665-6334

 

Kakaku.com: Launch of Japan’s Largest Restaurant Reservation Service for Overseas Visitors

TOKYO - Wednesday, 26. June 2024

Online reservations at over 35,000*1 restaurants available in English, Chinese (Simplified and Traditional) and Korean

(BUSINESS WIRE)--Tabelog*2, one of Japan’s largest restaurant search and reservation sites, has launched an online reservation service for visitors to Japan, which supports English, Chinese (Simplified and Traditional) and Korean. With reservations available at over 35,000 restaurants, it is the largest service of its kind in Japan.

*1As of June 26, 2024, based on internal research. Largest restaurant reservation service (instant reservations) for visitors to Japan
*2Tabelog is operated by Kakaku.com, Inc. one of Japan’s leading Internet companies.

Tabelog’s online reservation service for overseas visitors

To offer a more convenient way to find and reserve restaurants for the growing number of visitors to Japan, we have launched an online restaurant reservation service where reservations can be made in English, Chinese (Traditional and Simplified), and Korean.
*According to the Japan National Tourism Organization, the number of visitors to Japan is expected to exceed 3 million in May 2024 (up 60% from the previous year).

Features of Tabelog’s service are as follows:

    Search for restaurants in Japan by specifying a location, cuisine, budget, and the date and time you want to make a reservation.
    Select a restaurant based on detailed information about the restaurant, including menu, photos, and reviews posted by Japanese users.
    Check reservation availability using the calendar function and make online reservations directly on Tabelog.
    *Online reservations are currently only available for set menus and require credit card registration. In addition, there is a system usage fee of 440 yen (incl. tax) per person per reservation.

“Japan is currently the destination of choice for travelers from around the world, and many of them want to experience Japan’s food culture. However, there is still a shortage of restaurants equipped to communicate with and take reservations from overseas visitors leading to a situation where only a handful of well-known restaurants are attracting visitors to Japan,” said Taku Kounoike, Head of Tabelog. “As a Japanese gourmet media, we want to support travelers in experiencing the deeper charm of Japan, by showcasing a wide range of excellent restaurants across the country, and by providing a service that enables users to make online reservations. We sincerely hope that your travel experience in Japan will become more fulfilling than ever before.”

Links to the different language versions of Tabelog:
- English: https://tabelog.com/en/
- Simplified Chinese: https://tabelog.com/cn/
- Traditional Chinese: https://tabelog.com/tw/
- Korean: https://tabelog.com/kr/

*Ongoing modifications and improvements to the site may result in changes to the user interface and performance.

About Tabelog

Tabelog provides information on almost all restaurants in Japan, and users can choose restaurants catering to their specific preferences, based on information provided by the restaurants themselves, as well as reviews and photos posted by users. The service receives high marks from users for offering comprehensive information about restaurants and a highly convenient user interface. As of March 2024, it has become one of Japan’s largest restaurant search and reservation services, with approximately 93.5 million monthly users.

About Kakaku.com, Inc. (https://corporate.kakaku.com/?lang=en)

Established in 1997, Kakaku.com, Inc. (TOKYO:2371) is a Japanese internet company operating various web services, including the purchasing support site "Kakaku.com", the restaurant search and reservation service "Tabelog", and the comprehensive job search service "Kyujin Box". In April 2024, the company launched "Jobcube", a comprehensive search site for jobseekers, in the United States.
Service Overview: https://corporate.kakaku.com/company/service/?lang=en

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240626189960/en/

Permalink
https://www.aetoswire.com/en/news/2606202440122

Contacts

Kakaku.com, Inc.
Public Relations and Investor Relations Office
pr@kakaku.com

Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

 DARMSTADT, Germany 

Not intended for UK-, US- or Canada-based media

(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). The decision follows a pre-planned interim analysis performed by the study’s Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary objective of prolonging event-free survival. Top-line safety data were overall compatible with the chemo-radio sensitizing properties of xevinapant. The company will conduct an in-depth review of the data and will share the results in a peer-reviewed forum.

LA SCCHN has proven to be a difficult-to-treat form of cancer. CRT has remained the standard of care for decades, despite multiple studies designed to improve outcomes with new treatment approaches, including multiple immunotherapy trials.

“We sincerely thank the patients, caregivers and clinical investigators who participated in this trial,” said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business sector of Merck. “While we are disappointed by these results, we remain steadfast in our commitment to develop transformative medicines within our oncology portfolio for areas of high unmet need.”

Given the totality of the data, the company decided to also stop the Phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy, compared to placebo plus radiotherapy) in patients who underwent resection of locally advanced head and neck cancer.

Merck is working to develop and deliver new treatment options that exploit the vulnerabilities of tumor cells. The company is exploring modalities including antibody-drug conjugates (ADCs) and DNA damage response (DDR) inhibitors, across multiple tumor types, including many that have proven difficult to treat where there are significant unmet needs for patients. The company’s support for the head and neck cancer community remains steadfast with Erbitux®, approved in combination with radiotherapy for the initial treatment of locally advanced SCCHN, and which continues to be studied in more than 200 active clinical trials, including at least 15 Phase III studies.

About Xevinapant

Xevinapant (formerly known as Debio 1143) is an investigational potent oral small-molecule IAP (inhibitor of apoptosis protein) inhibitor. In March 2021, Merck gained exclusive rights from Debiopharm International SA to develop and commercialize xevinapant worldwide. Xevinapant is not approved for any use anywhere in the world.

Advancing the Future of Cancer Care

At Merck we strive every day to improve the futures of people living with cancer. Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at its core. We are determined to maximize the impact of our standard-of-care treatments and to continue pioneering novel medicines. Our vision is to create a world where more cancer patients will become cancer survivors. Learn more at www.merckgrouponcology.com.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240624549928/en/

Permalink

https://aetoswire.com/en/news/54086430

Contacts

 

Media Relations

gangolf.schrimpf@merckgroup.com

Phone: +49 151 1454-9591

Investor Relations

investor.relations@merckgroup.com

Phone: +49 6151 72-3321

NetApp Earns AAA Rating for Industry-First AI-Driven On-Box Ransomware Detection Solution

 SAN JOSE, Calif.

NetApp sets new standard for secure storage with third-party validated ransomware detection accuracy of 99 percent

(BUSINESS WIRE) -- NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that NetApp ONTAP® Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI) has received a AAA rating from SE Labs, an independently-owned and run testing company that assesses security products and services. SE Labs validated the protection effectiveness of NetApp ARP/AI with 99 percent recall—a metric that measures malware detection rates—for ransomware attacks, while noting the absence of false positives.

When responding to ransomware attacks, seconds can make the difference between ensuring continuity and a massive business disruption. Organizations need fast, automated, and accurate detection and response capabilities built into their primary storage systems to minimize the damage done by lost production data and downtime. NetApp ARP/AI, with its AI-powered ransomware detection capability, addresses this gap by providing real-time detection and response to minimize the impact of cybersecurity threats.

SE Labs rigorously tested NetApp ARP/AI against hundreds of known ransomware variants with impressive results. NetApp ARP/AI demonstrated 99 percent detection of advanced ransomware attacks. NetApp ARP/AI also achieved 100 percent detection of legitimate files without flagging any false positives, indicating a strong ability to operate in a business context without contributing to alert fatigue.

Ensuring data is secure against internal and external threats is a critical part of making data infrastructure intelligent which then empowers customers to turn disruption into opportunity. This validation of NetApp’s AI-powered ransomware detection capabilities underscores how NetApp is staying at the forefront of AI innovation by both enabling AI adoption and applying AI to data services. NetApp’s newly released more powerful, all-flash storage systems help enterprises leverage their data to drive AI workloads, built on NetApp’s secure storage infrastructure.

"NetApp has passed a significant milestone in the fight against ransomware as the first and only storage vendor to offer AI-driven on-box ransomware detection with externally validated top-notch protection effectiveness,” said Dr. Arun Gururajan, Vice President, Research & Data Science at NetApp. “Ransomware detection methodologies that rely only on backup data are too slow to effectively mitigate the risks businesses face from cybersecurity threats. NetApp ARP/AI hardens enterprise storage by providing robust, built-in detection capabilities that can respond to ransomware threats in real time. The AAA rating we achieved from SE Labs is the result of our commitment to innovation in intelligent data infrastructure and our drive to find new ways to make NetApp the most secure storage on the planet.”

By embedding ransomware detection in storage, NetApp ARP/AI helps customers improve their cyber resilience while reducing the operational burden and skills required to maintain their intelligent data infrastructure. NetApp ARP/AI’s detection technology continuously adapts and evolves as new ransomware variants are discovered. This continuous retraining on the latest ransomware strains ensures that NetApp ARP/AI remains at the forefront of protection effectiveness, offering organizations a future-proof defense against the dynamic ransomware landscape.

To see the full results of the tests, read the SE Labs Report.

NetApp ARP/AI is currently in tech preview. Customers can request to participate in the tech preview by reaching out to their NetApp sales representative.

Additional Resources

NetApp, the First and Leading AI-Powered Autonomous Ransomware Protection Native to Storage Achieves Remarkable AAA Rating and 99% Detection Accuracy and 100% Legitimate Accuracy in SE Labs Validation Testing

Protect, Detect, Recover; Guaranteed

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240626446291/en/

Permalink

https://www.aetoswire.com/en/news/2606202440119

Contacts

Media Contact:

Kenya Hayes

NetApp

kenya.hayes@netapp.com

Investor Contact:

Kris Newton

NetApp

kris.newton@netapp.com

Takeda Announces New Assignments of Directors

 

OSAKA, Japan - 

(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today.

Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The Audit and Supervisory Committee, the Nomination Committee and the Compensation Committee will be composed solely of external directors including their chairs.

Takeda highly values strong, independent governance and its Board of Directors helps to ensure that all decisions and actions are in the best interests of global stakeholders and aligned with the company’s values. This robust corporate governance model has been, and will continue to be, critical to Takeda's success.

Details of the new assignments are as follows:

1. New Assignment of Directors Who Are Not Audit and Supervisory Committee Members (Effective June 26, 2024)

Name

Category

Role

Christophe Weber

Internal

Existing

Representative Director, President & Chief Executive Officer

Milano Furuta

Internal

New

Director, Chief Financial Officer

Andrew Plump

Internal

Existing

Director, President, Research & Development

Masami Iijima

External

Existing

External Director, Chair of the Board Meeting

Ian Clark

External

Existing

External Director

Steven Gillis

External

Existing

External Director

Emiko Higashi

External

New

External Director

John Maraganore

External

Existing

External Director

Michel Orsinger

External

Existing

External Director

Miki Tsusaka

External

Existing

External Director

2. Directors Who Are Audit and Supervisory Committee Members (Effective June 26, 2024)

Name

Category

Role

Koji Hatsukawa

External

Existing

External Director, Head of Audit and Supervisory Committee

Jean-Luc Butel

External

New

External Director, Audit and Supervisory Committee Member

Yoshiaki Fujimori

External

Existing

External Director, Audit and Supervisory Committee Member

Kimberly A. Reed

External

Existing

External Director, Audit and Supervisory Committee Member

3. New Assignment of Nomination Committee and Compensation Committee Members (Effective June 26, 2024)

Nomination committee:

Masami Iijima (Chairperson), Steven Gillis, Emiko Higashi, Michel Orsinger, Jean-Luc Butel, and Yoshiaki Fujimori

(Observer: Christophe Weber)

Compensation committee:

Emiko Higashi (Chairperson), John Maraganore, Michel Orsinger, and Kimberly A. Reed

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240619545549/en/

Permalink

https://www.aetoswire.com/en/news/2606202440108

Contacts

Media Contacts:

Japanese Media

Shoko Honda

shoko.honda@takeda.com

+81 (0) 70-2687-3620

U.S. and International Media

Brendan Jennings

brendan.jennings@takeda.com

+81 (0) 80-2705-8259